Biogen Inc.
BIIB Healthcare Drug Manufacturers General
Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024. In the quarter to June 2026, revenue grew 3.42%, EPS fell 84.8%, free cash flow grew 103.3% and total debt rose 16.0%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.
Follow BIIB
Biogen Inc. (BIIB) Revenue
Biogen Inc.'s revenue for fiscal 2025 was $9.9B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $10.0B. Over the past ten years it has ranged from $9.7B (fiscal 2024) to $14.4B (fiscal 2019); the current reading is higher than 27% of that period. Biogen Inc. ranks 14th of 18 Drug Manufacturers General companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $9.9B | 2.22% |
| FY2024 | $9.7B | (1.62%) |
| FY2023 | $9.8B | (3.32%) |
| FY2022 | $10.2B | (7.36%) |
| FY2021 | $11.0B | (18.32%) |
| FY2020 | $13.4B | (6.49%) |
| FY2019 | $14.4B | 6.88% |
| FY2018 | $13.5B | 9.61% |
| FY2017 | $12.3B | 7.21% |
| FY2016 | $11.4B | 6.36% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $2.7B | 10.42% |
| Mar 2026 | $2.5B | 8.70% |
| Dec 2025 | $2.3B | (10.07%) |
| Sep 2025 | $2.5B | (4.19%) |
| 42 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| PFE Pfizer Inc. compare | $63.7B |
| AZN AstraZeneca PLC compare | $61.4B |
| SNY Sanofi compare | $57.0B |
| NVO Novo Nordisk A/S compare | $51.5B |
| BMY Bristol Myers Squibb Company compare | $49.2B |
| GSK GSK PLC Sponsored ADR compare | $44.5B |
| AMGN Amgen Inc. compare | $38.1B |
| GILD Gilead Sciences, Inc. compare | $30.5B |
| BIIB Biogen Inc. | $10.0B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on BIIB
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement